Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Arsenic trioxide depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of Notch pathway.

Toxicology letters·2013

Same author

A prospective, randomized, open-label study comparing the efficacy and safety of preprandial and prandial insulin in combination with acarbose in elderly, insulin-requiring patients with type 2 diabetes mellitus.

Diabetes technology & therapeutics·2013

Same author

Synthesis of the C-18-C-34 fragment of amphidinolides C, C2, and C3.

Organic letters·2013

Same author

Synthesis of the C-1-C-17 fragment of amphidinolides C, C2, C3, and F.

Organic letters·2013

Same author

77Se solid-state NMR of As2Se3, As4Se4 and As4Se3 crystals: a combined experimental and computational study.

Physical chemistry chemical physics : PCCP·2013

Same author

Nanocellulose electroconductive composites.

Nanoscale·2013

Search research articles

Related Experiment Video

Updated: Jul 8, 2026

A Spheroid Killing Assay by CAR T Cells

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

Engineering cells for solid tumor therapy.

Yuyang Xiao¹, Yue Wu¹, Qinyan Cao¹

¹State Key Laboratory of Microbial Technology, School of Food and Pharmaceutical Engineering, Nanjing Normal University, Nanjing 210023, China.

Trends in Pharmacological Sciences

|July 6, 2026

Summary

This summary is machine-generated.

This review presents a framework for engineering living cells with nonliving drugs to improve solid tumor treatment. It guides rational design for enhanced cell therapies, focusing on penetration, immune resistance, and safety.

Keywords:

cell therapy controlled release drug delivery engineering cells solid tumor therapy

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Published on: June 14, 2024

Related Experiment Videos

Last Updated: Jul 8, 2026

A Spheroid Killing Assay by CAR T Cells

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Published on: June 14, 2024

Area of Science:

Biomedical Engineering
Oncology
Cell Therapy

Background:

Living cell therapy and nonliving drugs are established treatments for solid tumors.
Combining cells and drugs offers synergistic therapeutic potential.
Current engineering strategies may not fully exploit this synergy or overcome tumor-specific barriers.

Purpose of the Study:

To provide a decision framework for matching engineering strategies to cell types and drug properties.
To discuss methods for enhancing engineered cells to overcome solid tumor challenges.
To guide the development of next-generation engineered cell therapies for improved clinical outcomes.

Main Methods:

Literature review and synthesis of existing research on cell-drug engineering.
Development of a decision framework for selecting appropriate engineering strategies.
Discussion of functional enhancements for cell therapies targeting solid tumors.

Main Results:

A framework is proposed to ensure baseline-qualified engineered cells by matching strategies to cell and drug characteristics.
Strategies are outlined for improving cell penetration, immunosuppression resistance, and controlled drug release in solid tumors.
Emerging safety considerations for clinical translation are discussed.

Conclusions:

Rational design of engineered cell therapies is crucial for maximizing synergy between living cells and nonliving drugs.
Addressing solid tumor-specific barriers through functional enhancement is key to therapeutic success.
This review provides guidance for developing safer and more effective next-generation cell therapies.